文献速递药物相互作用药物不良反应与药物警戒

通过文献分析与电子健康记录验证发现药代动力学药物相互作用引发的严重不良反应

Discovering Severe Adverse Reactions From Pharmacokinetic Drug-Drug Interactions Through Literature Analysis and Electronic Health Record Verification.
PubMed 文献 · Clin Pharmacol Ther · 2024-11-25

研究利用自然语言处理技术从PubMed文献中提取药物相互作用导致的严重不良反应信号,并用两家电子健康记录数据库验证,发现111个信号中17个具统计学显著性,9个未记载于DrugBank。

要点

  • NLP可从文献中高效提取药物相互作用-严重不良反应信号。
  • 多源EHR验证可识别上市前试验未发现的严重不良反应。
  • 9个新信号未在DrugBank中记录,提示药物警戒新方向。

核心结论

  • 利用NLP从文献提取药物相互作用-严重不良反应信号并经多源电子健康记录验证,可发现上市前试验和现有知识库未记录的临床相关严重不良反应。

研究设计与样本

  • 使用PubTator Central进行命名实体识别,SciFive进行关系抽取。
  • 提取的信号与DrugBank交叉比对,并用VUMC和All of Us电子健康记录通过逻辑回归验证。

主要发现

  • 共识别111个药物相互作用-严重不良反应信号。
  • 17个信号具统计学显著性,其中13个仅由一家EHR验证,4个由两家EHR共同验证。
  • 9个信号此前未记录于DrugBank。
  • 新信号包括美沙酮-环丙沙星-呼吸抑制、辛伐他汀-氟康唑-横纹肌溶解、秋水仙碱-环孢素-横纹肌溶解等。
  • 比值比范围为1.9至35.83,P值范围为<0.001至0.017。

临床怎么用

  • 临床药师可关注文献挖掘结合EHR验证的药物相互作用-严重不良反应信号,用于药物警戒和不良反应监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While drug-drug interactions (DDIs) and their pharmacokinetic (PK) mechanisms are well-studied prior to drug approval, severe adverse drug reactions (SADRs) caused by DDIs often remain underrecognized due to limitations in pre-marketing clinical trials. To address this gap, our study utilized a literature database, applied natural language processing (NLP) techniques, and conducted multi-source electronic health record (EHR) validation to uncover underrecognized DDI-SADR signals that warrant further investigation. PubMed abstracts related to DDIs from January 1962 to December 2023 were retrieved. We utilized PubTator Central for Named Entity Recognition (NER) to identify drugs and SADRs and employed SciFive for Relation Extraction (RE) to extract DDI-SADR signals. The extracted signals were cross-referenced with the DrugBank database and validated using logistic regression, considering risk factors including patient demographics, drug usage, and comorbidities, based on EHRs from Vanderbilt University Medical Center (VUMC) and the All of Us research program. From 160,321 abstracts, we identified 111 DDI-SADR signals. Seventeen were statistically significant (13 by one EHR and 4 by both EHR databases), with 9 being previously not recorded in the DrugBank. These included methadone-ciprofloxacin-respiratory depression, oxycodone-fluvoxamine-clonus, tramadol-fluconazole-hallucination, simvastatin-fluconazole-rhabdomyolysis, ibrutinib-amiodarone-atrial fibrillation, fentanyl-diltiazem-delirium, clarithromycin-voriconazole-acute kidney injury, colchicine-cyclosporine-rhabdomyolysis, and methadone-voriconazole-arrhythmia (odds ratios (ORs) ranged from 1.9 to 35.83, with P-values ranging from < 0.001 to 0.017). Utilizing NLP to extract DDI-SADRs from Biomedical Literature and validating these findings through multiple-source EHRs represents a pioneering approach in pharmacovigilance. This method uncovers clinically relevant SADRs resulting from DDIs that were not evident in pre-marketing trials or the existing DDI knowledge base.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jeong E, Su Y, Li L, et al. Discovering Severe Adverse Reactions From Pharmacokinetic Drug-Drug Interactions Through Literature Analysis and Electronic Health Record Verification. Clin Pharmacol Ther. 2024. PMID: 39585167. doi:10.1002/cpt.3500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。